- Home
- RFIL vs NGEN Comparison
RFIL vs NGEN Comparison
Compare RFIL & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFIL | NGEN |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.3M | 208.6M |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RFIL | NGEN |
|---|---|---|
| Price | $8.01 | $1.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | 294.6K | ★ 442.0K |
| Earning Date | 09-14-2026 | 11-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $55,325,000.00 | N/A |
| Revenue This Year | $9.73 | N/A |
| Revenue Next Year | $10.06 | N/A |
| P/E Ratio | $41.48 | ★ N/A |
| Revenue Growth | ★ 10.22 | N/A |
| 52 Week Low | $5.54 | $1.58 |
| 52 Week High | $22.30 | $5.97 |
Technical Indicators
Market Signals| Indicator | RFIL | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 34.13 | 38.68 |
| Support Level | $7.77 | $1.70 |
| Resistance Level | $8.50 | $1.82 |
| Average True Range (ATR) | 0.30 | 0.10 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 26.92 | 11.60 |
Price Performance
Historical ComparisonAbout RFIL RF Industries Ltd.
RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.